Monoclonal Antibody Therapy
Antibodies are a key component of the adaptive immune response, playing a central role in both in the recognition of foreign antigens and the stimulation of an immune response to them. It is not surprising therefore, that many immunotherapeutic approaches involve the use of antibodies. The advent of monoclonal antibody technology has made it possible to raise antibodies against specific antigens such as the unusual antigens that are presented on the surfaces of tumors.
A number of therapeutic monoclonal antibodies have been approved for use in humans; approvals mentioned here are by the U.S. Food and Drug Administration (FDA).
| Antibody | Brand name | Approval date | Type | Target | Approved treatment(s) |
|---|---|---|---|---|---|
| Alemtuzumab | Campath | 2001 | humanized | CD52 | Chronic lymphocytic leukemia |
| Bevacizumab | Avastin | 2004 | humanized | vascular endothelial growth factor | colorectal cancer |
| Brentuximab vedotin | Adcetris | 2011 | chimeric | CD30 | Hodgkin lymphoma, Anaplastic large-cell lymphoma |
| Cetuximab | Erbitux | 2004 | chimeric | epidermal growth factor receptor | colorectal cancer |
| Gemtuzumab ozogamicin | Mylotarg | 2000 | humanized | CD33 | acute myelogenous leukemia (with calicheamicin) |
| Ibritumomab tiuxetan | Zevalin | 2002 | murine | CD20 | non-Hodgkin lymphoma (with yttrium-90 or indium-111) |
| Panitumumab | Vectibix | 2006 | human | epidermal growth factor receptor | colorectal cancer |
| Rituximab | Rituxan, Mabthera | 1997 | chimeric | CD20 | non-Hodgkin lymphoma |
| Trastuzumab | Herceptin | 1998 | humanized | ErbB2 | breast cancer |
Read more about this topic: Cancer Immunotherapy
Famous quotes containing the word therapy:
“Show business is the best possible therapy for remorse.”
—Anita Loos (1888–1981)